Absci Corporation
NASDAQ:ABSIBiotechnology
+$0.08 today
- Market cap
- $1.41B
- Beta
- 2.46
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$0.77
Volume 5.66M
Average 5.10M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Absci Corporation
NASDAQ:ABSI
Intrinsic Alpha fair value
Locked
Current Price
$8.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | -21.3% | +80.6% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at -21.3% over three years. Forward estimates point to Revenue at +80.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
AbCellera Biologics Inc. NASDAQ:ABCL | $3.75B | $11.49 | Not rated | -11.4 | +201.09% |
Generate Biomedicines, Inc. NASDAQ:GENB | $1.55B | $12.07 | Not rated | -3.5 | — |
Continue the stock analysis
Jump to another research area for this company.